TKMR, Tekmira Pharmaceuticals Corporation
TKMR reported that it has entered into a settlement agreement with Alnylam Pharmaceuticals, Inc. that resolves all litigation between the companies, and has signed a new licensing agreement that restructures the relationship and provides clarity on all intellectual property and licensing issues between the companies.
As a result of the restructuring and new agreements, TKMR will receive $65 million within 10 days and is eligible to receive $10 million in near-term milestone payments expected to be received in 2013.
TKMR is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners.
RNAi therapeutics have the potential to treat a broad number of human diseases by “silencing” disease causing genes. The discoverers of RNAi, a gene silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi therapeutics, such as “siRNAs,” require delivery technology to be effective systemically.
More about TKMR at www.tekmirapharm.com.
Read Full
No comments:
Post a Comment